What is the Oncocyte Corporation stock price forecast?

Oncocyte Corporation is currently trading at $6.03. View real-time AI analysis on Alpha Lenz.

What is Oncocyte Corporation insider trading activity?

View the latest insider trading data for Oncocyte Corporation on Alpha Lenz.

What is Oncocyte Corporation's P/E ratio?

Oncocyte Corporation's P/E ratio is -1.3.

Oncocyte Corporation

NASDAQ · OCX

$6.03+0.08(+1.34%)Pre-market

Ask about Oncocyte Corporation's future dividend policy...

Alpha Chat Insight

“Oncocyte Corporation trades at a P/E of -1.3 (undervalued) with modest ROE of -1480.7%.”

Ask for details →

Company Overview

Oncocyte Corporation is a biotechnology company focused on the development of molecular diagnostic tests for the detection of cancer. The primary function of Oncocyte is to improve patient outcomes by enhancing cancer diagnosis and monitoring through advanced genomic testing technologies. Its tests are designed to empower physicians with precise information, enabling more informed decisions regarding cancer treatment and management. Operating in the healthcare sector, Oncocyte plays a vital role in the fields of oncology and precision medicine, as it works towards personalized treatment options. The company’s mission is also to address the limitations of existing diagnostic methods by providing more accurate and less invasive alternatives. With a commitment to research and innovation, Oncocyte's offerings have the potential to significantly impact the early detection and treatment efficacy of various cancers. By focusing on unmet needs in the cancer diagnosis landscape, Oncocyte Corporation contributes to the broader healthcare market in efforts to improve patient care and clinical outcomes.

CEOMr. Joshua Riggs

Websitehttps://imdxinc.com

SectorHealthcare

IndustryDiagnostics & Research

Employees46

Company Statistics

FY 2024

Profile

$78.82MMarket Cap

$1.88MRevenue

0.00Shares Out

46Employees

Margins

39.34%Gross

-1128.18%EBITDA

-1235.89%Operating

-3225.04%Pre-Tax

-3225.04%Net

Valuation

-1.30P/E

-6.42P/B

41.90EV/Sales

-3.48EV/EBITDA

-3.71P/FCF

Growth (CAGR)

-5.06%Rev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-110.32%ROA

-1480.67%ROE

-110.17%ROIC

Financial Health

$8.64MCash & Cash Equivalents

$38.72MNet Debt

-385.82%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Oncocyte Corporation trades at a P/E of -1.3 (undervalued) with modest ROE of -1480.7%.”

Ask for details →

Frequently Asked Questions

Oncocyte Corporation (ticker: OCX) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 46 employees. Market cap is $79M.

The current price is $6.03 with a P/E ratio of -1.3x and P/B of -6.42x.

ROE is -1480.67% and operating margin is -1235.89%. Annual revenue is $2M.